University of California San Francisco

Marion Peters - 144
Marion
Peters
MD

Professor, Department of Medicine
John V. Carbone, M.D., Endowed Chair in Medicine
Chief of Hepatology Research

Address

513 Parnassus Avenue, MSB, #357
San Francisco, CA 94143
United States

Email: [email protected]
Phone: 415-502-0318
Fax: 415-476-0659

Biography

Dr. Marion Peters is a Professor of Medicine and holds the John V. Carbone, M.D., Endowed Chair in Medicine. She is also Chief of Hepatology Research. Dr. Peters is especially interested in the immunology of chronic liver diseases, particularly viral and autoimmune hepatitis. Her research activities include studies of transgenic mouse models of liver specific T cell responses, HIV and HCV coinfection, and alcohol and HCV infection.

Dr. Peters graduated from Melbourne University Medical School, Australia in 1972. She trained in gastroenterology, hepatology and immunology at St. Vincent's Hospital, Melbourne, University of Southern California and National Institutes of Health. She was Chief of Hepatology and medical director of Liver Transplantation at Washington University School of Medicine from 1985 to 1998.

Education

Education

Melbourne University Medical School, Melbourne, Australia, M.B.B.S., 1972, Medicine
St. Vincent's Hospital Medical School, Melbourne, Australia, Medicine
Melbourne University, M.D., 1991, Medicine/Immunology

Residencies

1973-76 Resident and Registrar in Internal Medicine, St.Vincent's Hospital, Melbourne, Australia

1976-77 Clinical Research Registrar to Dr. I. R. Mackay, Royal Melbourne Hospital and The Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia

Board Certifications

American Board of Internal Medicine, Internal Medicine

Clinical Expertise

Alcoholic Liver Disease
Autoimmune Hepatitis
Benign Liver Tumors
Cirrhosis
Fulminant Hepatic Failure
Hepatitis B
Hepatitis C
Hepatocellular Carcinoma (Liver Cancer)
Live Donor Liver Transplantation
Liver Transplantation
Nonalcoholic Fatty Liver Disease
Primary Biliary Cirrhosis
Primary Sclerosing Cholangitis

Clinical Trials

  1. Nitazoxanide Plus Ribavirin and Peginterferon for Therapy of Treatment Naive HCV Genotype 1 and HIV Coinfected Subjects (NCT00991289)
    Related Conditions: HIV/AIDS, Hepatitis C, Hepatitis A, Hepatitis| Start Date: | End Date:
  2. A Comparison of Adefovir and Tenofovir for the Treatment of Lamivudine-Resistant Hepatitis B Virus in People With HIV (NCT00033163)
    Related Conditions: HIV/AIDS, Hepatitis B, Hepatitis A, Hepatitis| Start Date: | End Date:

Program Affiliations

UCSF Liver Center

Member, UCSF Immunology Graduate Program

UCSF Helen Diller Family Comprehensive Cancer Center 

Grants and Funding

  • UCSF Liver Center | NIH | 1985-07-01 - 2023-05-31 | Role: Co-Investigator
  • NRSA Hepatology Training Grant | NIH | 2001-12-01 - 2022-06-30 | Role: Co-Principal Investigator
  • HIV status and reproductive aging affect liver fibrosis in HIV/HCV infected women | NIH | 2010-03-15 - 2013-02-28 | Role: Principal Investigator
  • General Clinical Research Center | NIH | 1974-12-01 - 2009-03-31 | Role: Co-Investigator
  • GENERAL CLINICAL RESEARCH CENTER | NIH | 1974-10-01 - 2009-03-31 | Role: Co-Investigator
  • HCV &ALCHOOL-- EPIDEMIOLOGY &HOST-VIRUS CORRELATES | NIH | 2000-09-30 - 2006-07-31 | Role: Principal Investigator
  • INTESTINAL IMMUNE RESPONSE INFLAMMATORY BOWL DISEASE | NIH | 1995-09-30 - 2001-08-31 | Role: Principal Investigator
  • INTESTINAL IMMUNE RESPONSE IN INFLAMMATORY BOWEL DISEASE | NIH | 1991-06-25 - 1995-10-31 | Role: Principal Investigator

Research Narrative

My major interest is in viral hepatitis and the role of the host immune response. My work focuses on interactions among alcohol use, cannabis use and HIV co-infection on fibrotic outcomes of HCV infection. We are currently evaluating the  predictors of progression of liver disease in HIV and HCV coinfected women within the Women's Interagency HIV Study (WIHS): the role of alcohol, cannabis, HIV status and control as well as reproductive aging on the severity and rate of progression of liver disease.

We are also studying adherence to antiretroviral therapy in HIV/HCV co-infected women and on HCV-specific and innate immune responses in persons co-infected with HCV and HIV. I work within the AIDS Clinical Trial Group to develop clinical trials in viral hepatitis and HIV and within the Women's Interagency HIV Study (WIHS) to examine predictors of liver-related morbidity and mortality in a cohort of women with HIV/HCV infection.

 

Research Interests

Liver Injury and Repair
Viral hepatitis and the role of the host immune response.

Publications

MOST RECENT PUBLICATIONS FROM A TOTAL OF 158
  1. The Pathogenesis of Liver Disease in People Living With Human Immunodeficiency Virus: The Emerging Role of the Microbiome.
    Kardashian A, Peters MG, Tien PC, Price JC| | PubMed
  2. HCV treatment barriers among HIV/HCV co-infected patients in the US: a qualitative study to understand low uptake among marginalized populations in the DAA era.
    Nápoles TM, Batchelder AW, Lin A, Moran L, Johnson MO, Shumway M, Luetkemeyer AF, Peters MG, Eagen KV, Riley ED| | PubMed
  3. Determinants of Liver Complications Among HIV/Hepatitis B Virus-Coinfected Patients.
    Lo Re V, Newcomb CW, Carbonari DM, Roy JA, Althoff KN, Kitahata MM, Reddy KR, Lim JK, Silverberg MJ, Mayor AM, Horberg MA, Cachay ER, Kirk GD, Hull M, Gill J, Sterling TR, Kostman JR, Peters MG, Moore RD, Klein MB, Kim HN, North American AIDS Cohort Collaboration on Research and Design of IeDEA| | PubMed
  4. HIV and the liver.
    Sherman KE, Peters MG, Thomas DL| | PubMed
  5. Ledipasvir/Sofosbuvir for 8 Weeks to Treat Acute Hepatitis C Virus Infections in Men With Human Immunodeficiency Virus Infections: Sofosbuvir-Containing Regimens Without Interferon for Treatment of Acute HCV in HIV-1 Infected Individuals.
    Naggie S, Fierer DS, Hughes MD, Kim AY, Luetkemeyer A, Vu V, Roa J, Rwema S, Brainard DM, McHutchison JG, Peters MG, Kiser JJ, Marks KM, Chung RT, Acquired Immunodeficiency Syndrome Clinical Trials Group (ACTG) A5327 Study Team| | PubMed
  6. Metabolic syndrome and liver steatosis occur at lower body mass index in US Asian patients with chronic hepatitis B.
    Clarke WT, Miranda J, Neidich E, Hudock R, Peters MG, Kelly EM| | PubMed
  7. Screening and Prophylaxis to Prevent Hepatitis B Reactivation: Introduction and Immunology.
    Sasadeusz J, Grigg A, Hughes PD, Lee Lim S, Lucas M, McColl G, McLachlan SA, Peters MG, Shackel N, Slavin M, Sundararajan V, Thompson A, Doyle J, Rickard J, De Cruz P, Gish RG, Visvanathan K| | PubMed
  8. Screening and Prophylaxis to Prevent Hepatitis B Reactivation: Patients with Hematological and Solid Tumor Malignancies.
    Sasadeusz J, Grigg A, Hughes PD, Lim SL, Lucas M, McColl G, McLachlan SA, Peters MG, Shackel N, Slavin M, Sundararajan V, Thompson A, Doyle J, Rickard J, De Cruz P, Gish RG, Visvanathan K| | PubMed
  9. Screening and Prophylaxis to Prevent Hepatitis B Reactivation: Transplant Recipients.
    Sasadeusz J, Grigg A, Hughes PD, Lee Lim S, Lucas M, McColl G, McLachlan SA, Peters MG, Shackel N, Slavin M, Sundararajan V, Thompson A, Doyle J, Rickard J, De Cruz P, Gish RG, Visvanathan K| | PubMed
  10. Screening and Prophylaxis to Prevent Hepatitis B Reactivation: Other Populations and Newer Agents.
    Sasadeusz J, Grigg A, Hughes PD, Lee Lim S, Lucas M, McColl G, McLachlan SA, Peters MG, Shackel N, Slavin M, Sundararajan V, Thompson A, Doyle J, Rickard J, De Cruz P, Gish RG, Visvanathan K| | PubMed
158
View all 158 Publications
MOST RECENT PUBLICATIONS FROM A TOTAL OF 158
  1. Diagnostic Utility of Pre-Genomic Hepatitis B RNA in the Evaluation of HBV/HIV Coinfection.
    Sherman KE, Rouster SD, Meeds H, Peters MG, Blackard JT, Horn PS, Archampong T, Kwara A, Anderson M, Stec M, Cloherty GA| | PubMed
  2. Chronic Hepatitis B Finite Treatment: Similar and Different Concerns With New Drug Classes.
    Peters MG, Yuen MF, Terrault N, Fry J, Lampertico P, Gane E, Hwang C, Stamm LM, Leus M, Maini MK, Mendez P, Lonjon-Domanec I, Berg T, Wang S, Mishra P, Donaldson E, Buchholz S, Miller V, Lenz O| | PubMed
  3. Design and analysis considerations for early phase clinical trials in hepatitis B (HBV) cure research: the ACTG A5394 study in persons with both HIV and HBV.
    Kang M, Price JC, Peters MG, Lewin SR, Sulkowski M| | PubMed
  4. Comparison of Antiretroviral Therapies in Pregnant Women Living With Human Immunodeficiency Virus and Hepatitis B Virus: A Randomized Controlled Trial.
    Bhattacharya D, Tierney C, Butler K, Kiweewa FM, Moodley D, Govender V, Vhembo T, Mohtashemi N, Ship H, Dula D, George K, Chaktoura N, Fowler MG, Peters MG, Currier JS| | PubMed
  5. Adverse Impact of HIV-1 on Long-term Outcomes Following HCV DAA Treatment: Final Results of ACTG A5320, the Viral Hepatitis C Infection Long-term Cohort Study (VHICS).
    Wyles DL, Kang M, Matining RM, Murphy RL, Peters MG| | PubMed
  6. Hepatocellular carcinoma presentation and prognosis among Nigerian adults with and without HIV.
    Davwar PM, Okeke E, Duguru M, Nyam D, Bell K, Odeghe EA, Oyeleke G, Lesi OA, Singh R, Kim KY, Imade G, Akanmu AS, Sagay AS, Ogunsola FT, Peters MG, Roberts LR, Hou L, Murphy RL, Hawkins CA| | PubMed
  7. Introducing Norah Terrault, MD, MPH, Our 2023 AASLD President.
    Peters MG, Lai JC| | PubMed
  8. Brief Report: Impact of Antiretroviral Regimen on Pregnancy and Infant Outcomes in Women With HIV/ HBV Coinfection.
    Kiweewa FM, Tierney C, Butler K, Peters MG, Vhembo T, Moodley D, Govender V, Mohtashemi N, Ship H, Musoke P, Dula D, George K, Chakhtoura N, Fowler MG, Currier JS, Bhattacharya D| | PubMed
  9. Hepatitis B surface antigen and hepatitis B RNA changes in HIV/hepatitis B virus co-infected participants receiving hepatitis B virus-active antiretroviral therapy.
    Hawkins C, Kang M, Bhattacharya D, Cloherty G, Kuhns M, Matining R, Thio C, Samaneka W, Chinula L, Mulinda N, Badal-Faesen S, Sugandhavesa P, Lama J, Gaseitsiwe S, Holzmayer V, Anderson M, Murphy R, Peters M| | PubMed
  10. Continued Low Rates of Hepatitis C Virus (HCV) Recurrence in HCV/HIV- and HCV-Infected Participants Who Achieved Sustained Virologic Response After Direct-Acting Antiviral Treatment: Final Results From the AIDS Clinical Trials Group A5320 Viral Hepatitis
    Wyles DL, Kang M, Matining RM, Murphy RL, Peters MG| | PubMed
  11. Treatment Algorithm for Managing Chronic Hepatitis B Virus Infection in the United States: 2021 Update.
    Martin P, Nguyen MH, Dieterich DT, Lau DT, Janssen HLA, Peters MG, Jacobson IM| | PubMed
  12. Decreases in markers of monocyte/macrophage activation after hepatitis C eradication in HIV/hepatitis C virus coinfected women.
    French AL, Grennan D, Daubert E, Seaberg EC, Peters M, Augenbraun M, Fischl M, Kassaye S, Franco R, Kuniholm M, Adimora AA, Workowski K, Weber KM| | PubMed
  13. Risk of HCC With Hepatitis B Viremia Among HIV/HBV-Coinfected Persons in North America.
    Kim HN, Newcomb CW, Carbonari DM, Roy JA, Torgersen J, Althoff KN, Kitahata MM, Reddy KR, Lim JK, Silverberg MJ, Mayor AM, Horberg MA, Cachay ER, Kirk GD, Sun J, Hull M, Gill MJ, Sterling TR, Kostman JR, Peters MG, Moore RD, Klein MB, Lo Re V, North American AIDS Cohort Collaboration on Research, Design of IeDEA| | PubMed
  14. A Multiancestry Sex-Stratified Genome-Wide Association Study of Spontaneous Clearance of Hepatitis C Virus.
    Vergara C, Valencia A, Thio CL, Goedert JJ, Mangia A, Piazzolla V, Johnson E, Kral AH, O'Brien TR, Mehta SH, Kirk GD, Kim AY, Lauer GM, Chung RT, Cox AL, Peters MG, Khakoo SI, Alric L, Cramp ME, Donfield SM, Edlin BR, Busch MP, Alexander G, Rosen HR, Murphy EL, Wojcik GL, Taub MA, Thomas DL, Duggal P| | PubMed
  15. Hepatotoxicity and Liver-Related Mortality in Women of Childbearing Potential Living With Human Immunodeficiency Virus and High CD4 Cell Counts Initiating Efavirenz-Containing Regimens.
    Bhattacharya D, Gupta A, Tierney C, Huang S, Peters MG, Chipato T, Martinson F, Mohtashemi N, Dula D, George K, Chaktoura N, Klingman KL, Gnanashanmugam D, Currier JS, Fowler MG| | PubMed
  16. Trends in Hepatocellular Carcinoma Incidence and Risk Among Persons With HIV in the US and Canada, 1996-2015.
    Sun J, Althoff KN, Jing Y, Horberg MA, Buchacz K, Gill MJ, Justice AC, Rabkin CS, Goedert JJ, Sigel K, Cachay E, Park L, Lim JK, Kim HN, Lo Re V, Moore R, Sterling T, Peters MG, Achenbach CJ, Silverberg M, Thorne JE, Mayor AM, Crane HM, Kitahata MM, Klein M, Kirk GD, North American AIDS Cohort Collaboration on Research and Design of IeDEA| | PubMed
  17. Retrospective-prospective study of safety and efficacy of sofosbuvir-based direct-acting antivirals in HIV/HCV-coinfected participants with decompensated liver disease pre- or post-liver transplant.
    Peters MG, Kottilil S, Terrault N, Amara D, Husson J, Huprikar S, Florman S, Sulkowski MS, Durand CM, Luetkemeyer AF, Rogers R, Grab J, Haydel B, Blumberg E, Dove L, Emond J, Olthoff K, Smith C, Fishbein T, Masur H, Stock PG| | PubMed
  18. Correction: Multi-ancestry fine mapping of interferon lambda and the outcome of acute hepatitis C virus infection.
    Vergara C, Duggal P, Thio CL, Valencia A, O'Brien TR, Latanich R, Timp W, Johnson EO, Kral AH, Mangia A, Goedert JJ, Piazzola V, Mehta SH, Kirk GD, Peters MG, Donfield SM, Edlin BR, Busch MP, Alexander G, Murphy EL, Kim AY, Lauer GM, Chung RT, Cramp ME, Cox AL, Khakoo SI, Rosen HR, Alric L, Wheelan SJ, Wojcik GL, Thomas DL, Taub MA| | PubMed
  19. Multi-ancestry fine mapping of interferon lambda and the outcome of acute hepatitis C virus infection.
    Vergara C, Duggal P, Thio CL, Valencia A, O'Brien TR, Latanich R, Timp W, Johnson EO, Kral AH, Mangia A, Goedert JJ, Piazzola V, Mehta SH, Kirk GD, Peters MG, Donfield SM, Edlin BR, Busch MP, Alexander G, Murphy EL, Kim AY, Lauer GM, Chung RT, Cramp ME, Cox AL, Khakoo SI, Rosen HR, Alric L, Wheelan SJ, Wojcik GL, Thomas DL, Taub MA| | PubMed
  20. Association Between Seroclearance of Hepatitis B Surface Antigen and Long-term Clinical Outcomes of Patients With Chronic Hepatitis B Virus Infection: Systematic Review and Meta-analysis.
    Anderson RT, Choi HSJ, Lenz O, Peters MG, Janssen HLA, Mishra P, Donaldson E, Westman G, Buchholz S, Miller V, Hansen BE| | PubMed
  21. The Pathogenesis of Liver Disease in People Living With Human Immunodeficiency Virus: The Emerging Role of the Microbiome.
    Kardashian A, Peters MG, Tien PC, Price JC| | PubMed
  22. HCV treatment barriers among HIV/HCV co-infected patients in the US: a qualitative study to understand low uptake among marginalized populations in the DAA era.
    Nápoles TM, Batchelder AW, Lin A, Moran L, Johnson MO, Shumway M, Luetkemeyer AF, Peters MG, Eagen KV, Riley ED| | PubMed
  23. Determinants of Liver Complications Among HIV/Hepatitis B Virus-Coinfected Patients.
    Lo Re V, Newcomb CW, Carbonari DM, Roy JA, Althoff KN, Kitahata MM, Reddy KR, Lim JK, Silverberg MJ, Mayor AM, Horberg MA, Cachay ER, Kirk GD, Hull M, Gill J, Sterling TR, Kostman JR, Peters MG, Moore RD, Klein MB, Kim HN, North American AIDS Cohort Collaboration on Research and Design of IeDEA| | PubMed
  24. HIV and the liver.
    Sherman KE, Peters MG, Thomas DL| | PubMed
  25. Ledipasvir/Sofosbuvir for 8 Weeks to Treat Acute Hepatitis C Virus Infections in Men With Human Immunodeficiency Virus Infections: Sofosbuvir-Containing Regimens Without Interferon for Treatment of Acute HCV in HIV-1 Infected Individuals.
    Naggie S, Fierer DS, Hughes MD, Kim AY, Luetkemeyer A, Vu V, Roa J, Rwema S, Brainard DM, McHutchison JG, Peters MG, Kiser JJ, Marks KM, Chung RT, Acquired Immunodeficiency Syndrome Clinical Trials Group (ACTG) A5327 Study Team| | PubMed
  26. Metabolic syndrome and liver steatosis occur at lower body mass index in US Asian patients with chronic hepatitis B.
    Clarke WT, Miranda J, Neidich E, Hudock R, Peters MG, Kelly EM| | PubMed
  27. Screening and Prophylaxis to Prevent Hepatitis B Reactivation: Introduction and Immunology.
    Sasadeusz J, Grigg A, Hughes PD, Lee Lim S, Lucas M, McColl G, McLachlan SA, Peters MG, Shackel N, Slavin M, Sundararajan V, Thompson A, Doyle J, Rickard J, De Cruz P, Gish RG, Visvanathan K| | PubMed
  28. Screening and Prophylaxis to Prevent Hepatitis B Reactivation: Patients with Hematological and Solid Tumor Malignancies.
    Sasadeusz J, Grigg A, Hughes PD, Lim SL, Lucas M, McColl G, McLachlan SA, Peters MG, Shackel N, Slavin M, Sundararajan V, Thompson A, Doyle J, Rickard J, De Cruz P, Gish RG, Visvanathan K| | PubMed
  29. Screening and Prophylaxis to Prevent Hepatitis B Reactivation: Transplant Recipients.
    Sasadeusz J, Grigg A, Hughes PD, Lee Lim S, Lucas M, McColl G, McLachlan SA, Peters MG, Shackel N, Slavin M, Sundararajan V, Thompson A, Doyle J, Rickard J, De Cruz P, Gish RG, Visvanathan K| | PubMed
  30. Screening and Prophylaxis to Prevent Hepatitis B Reactivation: Other Populations and Newer Agents.
    Sasadeusz J, Grigg A, Hughes PD, Lee Lim S, Lucas M, McColl G, McLachlan SA, Peters MG, Shackel N, Slavin M, Sundararajan V, Thompson A, Doyle J, Rickard J, De Cruz P, Gish RG, Visvanathan K| | PubMed
  31. Post-sustained Virologic Response Liver Stiffness May Underestimate Fibrosis After Direct Acting Antiviral-containing Therapy.
    Kardashian A, McKinney J, Huynh N, Yu R, Peters M, Catalli L, Price JC| | PubMed
  32. Long-Term Use of Azathioprine in the Management of Autoimmune Hepatitis.
    Peters MG| | PubMed
  33. Therapeutic trials of biologics in primary biliary cholangitis: An open label study of abatacept and review of the literature.
    Bowlus CL, Yang GX, Liu CH, Johnson CR, Dhaliwal SS, Frank D, Levy C, Peters MG, Vierling JM, Gershwin ME| | PubMed
  34. Direct-acting antiviral treatment for HIV/HCV patients in safety net settings: patient and provider preferences.
    Shumway M, Luetkemeyer AF, Peters MG, Johnson MO, Napoles TM, Riley ED| | PubMed
  35. Hepatitis B Virus Infection: What Is Current and New.
    Peters MG| | PubMed
  36. Cost-effectiveness of Hepatitis B Virus Infection Screening and Treatment or Vaccination in 6 High-risk Populations in the United States.
    Chahal HS, Peters MG, Harris AM, McCabe D, Volberding P, Kahn JG| | PubMed
  37. Multi-Ancestry Genome-Wide Association Study of Spontaneous Clearance of Hepatitis C Virus.
    Vergara C, Thio CL, Johnson E, Kral AH, O'Brien TR, Goedert JJ, Mangia A, Piazzolla V, Mehta SH, Kirk GD, Kim AY, Lauer GM, Chung RT, Cox AL, Peters MG, Khakoo SI, Alric L, Cramp ME, Donfield SM, Edlin BR, Busch MP, Alexander G, Rosen HR, Murphy EL, Latanich R, Wojcik GL, Taub MA, Valencia A, Thomas DL, Duggal P| | PubMed
  38. Universal Screening of Pregnant Women for Hepatitis C: The Time Is Now.
    Jhaveri R, Broder T, Bhattacharya D, Peters MG, Kim AY, Jonas MM| | PubMed
  39. Risk of HBV reactivation in patients with B-cell lymphomas receiving obinutuzumab or rituximab immunochemotherapy.
    Kusumoto S, Arcaini L, Hong X, Jin J, Kim WS, Kwong YL, Peters MG, Tanaka Y, Zelenetz AD, Kuriki H, Fingerle-Rowson G, Nielsen T, Ueda E, Piper-Lepoutre H, Sellam G, Tobinai K| | PubMed
  40. A Tough Egg to Crack.
    Geha RM, Dhaliwal G, Peters MG, Manesh R| | PubMed
  41. Effects of sofosbuvir-based hepatitis C treatment on the pharmacokinetics of tenofovir in HIV/HCV-coinfected individuals receiving tenofovir disoproxil fumarate.
    MacBrayne CE, Marks KM, Fierer DS, Naggie S, Chung RT, Hughes MD, Kim AY, Peters MG, Brainard DM, Seifert SM, Castillo-Mancilla JR, Bushman LR, Anderson PL, Kiser JJ| | PubMed
  42. Hepatitis B virus infection.
    Yuen MF, Chen DS, Dusheiko GM, Janssen HLA, Lau DTY, Locarnini SA, Peters MG, Lai CL| | PubMed
  43. Similar Low Rates of HCV Recurrence in HCV/HIV- and HCV-Infected Participants who Achieved SVR After DAA Treatment: Interim Results From the ACTG A5320 Viral Hepatitis C Infection Long-term Cohort Study (V-HICS).
    Wyles DL, Kang M, Matining RM, Murphy RL, Peters MG, VHICS Study Team| | PubMed
  44. An Assessment of the Clinical Accuracy of Ultrasound in Diagnosing Cirrhosis in the Absence of Portal Hypertension.
    Kelly EMM, Feldstein VA, Parks M, Hudock R, Etheridge D, Peters MG| | PubMed
  45. Contribution of Liver Fibrosis and Microbial Translocation to Immune Activation in Persons Infected With HIV and/or Hepatitis C Virus.
    Reid M, Ma Y, Scherzer R, Price JC, French AL, Huhn GD, Plankey MW, Peters M, Grunfeld C, Tien PC| | PubMed
  46. Chronic hepatitis C virus infection and subsequent HIV viral load among women with HIV initiating antiretroviral therapy.
    Willis SJ, Cole SR, Westreich D, Edmonds A, Hurt CB, Albrecht S, Anastos K, Augenbraun M, Fischl M, French AL, Kalapila AG, Karim R, Peters MG, Plankey M, Seaberg EC, Tien PC, Adimora AA| | PubMed
  47. Macrophage Activation and the Tumor Necrosis Factor Cascade in Hepatitis C Disease Progression Among HIV-Infected Women Participating in the Women's Interagency HIV Study.
    French AL, Martin JW, Evans CT, Peters M, Kessaye SG, Nowicki M, Kuniholm M, Golub E, Augenbraun M, Desai SN, WIHS| | PubMed
  48. Moderate Alcohol Use Is Not Associated With Fibrosis Progression in Human Immunodeficiency Virus/Hepatitis C Virus-Coinfected Women: A Prospective Cohort Study.
    Kelly EM, Dodge JL, Bacchetti P, Sarkar M, French AL, Tien PC, Glesby MJ, Golub ET, Augenbraun M, Plankey M, Peters MG| | PubMed
  49. Human immunodeficiency virus and liver disease: A comprehensive update.
    Sherman KE, Peters MG, Thomas D| | PubMed
  50. Reproductive Aging and Hepatic Fibrosis Progression in Human Immunodeficiency Virus/Hepatitis C Virus-Coinfected Women.
    Sarkar M, Dodge JL, Greenblatt RM, Kuniholm MH, DeHovitz J, Plankey M, Kovacs A, French AL, Seaberg EC, Ofotokun I, Fischl M, Overton E, Kelly E, Bacchetti P, Peters MG, Women’s Interagency HIV Study| | PubMed
  51. Controlled attenuation parameter and magnetic resonance spectroscopy-measured liver steatosis are discordant in obese HIV-infected adults.
    Price JC, Dodge JL, Ma Y, Scherzer R, Korn N, Tillinghast K, Peters MG, Noworolski S, Tien PC| | PubMed
  52. The effect of HIV infection and HCV viremia on inflammatory mediators and hepatic injury-The Women's Interagency HIV Study.
    Keating SM, Dodge JL, Norris PJ, Heitman J, Gange SJ, French AL, Glesby MJ, Edlin BR, Latham PS, Villacres MC, Greenblatt RM, Peters MG, Women’s Interagency HIV Study| | PubMed
  53. Management of Autoimmune Hepatitis in Pregnant Women.
    Peters MG| | PubMed
  54. New Direct-Acting Antiviral Agents and Immunomodulators for Hepatitis B Virus Infection.
    Peters MG, Locarnini S| | PubMed
  55. Use of Current and New Endpoints in the Evaluation of Experimental Hepatitis B Therapeutics.
    Block TM, Locarnini S, McMahon BJ, Rehermann B, Peters MG| | PubMed
  56. Sofosbuvir Plus Ribavirin Without Interferon for Treatment of Acute Hepatitis C Virus Infection in HIV-1-Infected Individuals: SWIFT-C.
    Naggie S, Marks KM, Hughes M, Fierer DS, Macbrayne C, Kim A, Hollabaugh K, Roa J, Symonds B, Brainard DM, McHutchison JG, Peters MG, Kiser JJ, Chung R, AIDS Clinical Trials Group (ACTG) A5327 Study Team| | PubMed
  57. Histology Rings True.
    Geha R, Peters M, Gill RM, Dhaliwal G| | PubMed
  58. Human immunodeficiency virus-infected and uninfected adults with non-genotype 3 hepatitis C virus have less hepatic steatosis than adults with neither infection.
    Price JC, Ma Y, Scherzer R, Korn N, Tillinghast K, Peters MG, Noworolski SM, Tien PC| | PubMed
  59. Sonography Predicts Liver Steatosis in Patients With Chronic Hepatitis B.
    Kelly EM, Feldstein VA, Etheridge D, Hudock R, Peters MG| | PubMed
  60. Sex differences in the association of HIV infection with hepatic steatosis.
    Kardashian A, Ma Y, Scherzer R, Price JC, Sarkar M, Korn N, Tillinghast K, Peters MG, Noworolski SM, Tien PC| | PubMed
  61. Autoimmune hepatitis: review of histologic features included in the simplified criteria proposed by the international autoimmune hepatitis group and proposal for new histologic criteria.
    Balitzer D, Shafizadeh N, Peters MG, Ferrell LD, Alshak N, Kakar S| | PubMed
  62. Advancing the regulatory path on hepatitis B virus treatment and curative research: a stakeholders consultation.
    Liu J, Goicochea P, Block T, Brosgart CL, Donaldson EF, Lenz O, Gee Lim S, Marins EG, Mishra P, Peters MG, Miller V| | PubMed
  63. Screening for hepatocellular carcinoma: What is missing?
    Mehta NJ, Celik AD, Peters MG| | PubMed
  64. Risk of End-Stage Liver Disease in HIV-Viral Hepatitis Coinfected Persons in North America From the Early to Modern Antiretroviral Therapy Eras.
    Klein MB, Althoff KN, Jing Y, Lau B, Kitahata M, Lo Re V, Kirk GD, Hull M, Kim HN, Sebastiani G, Moodie EE, Silverberg MJ, Sterling TR, Thorne JE, Cescon A, Napravnik S, Eron J, Gill MJ, Justice A, Peters MG, Goedert JJ, Mayor A, Thio CL, Cachay ER, Moore R, North American AIDS Cohort Collaboration on Research and Design of IeDEA, North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of IeDEA| | PubMed
  65. Hepatic fibrosis and immune phenotype vary by HCV viremia in HCV/HIV co-infected subjects: A Women's interagency HIV study.
    Desai SN, Dodge JL, Landay AL, Glesby MJ, Latham PS, Villacres MC, French AL, Gange SJ, Greenblatt RM, Peters MG| | PubMed
  66. Isolated Hepatitis B Core Antibody Status Is Not Associated With Accelerated Liver Disease Progression in HIV/Hepatitis C Coinfection.
    French AL, Hotton A, Young M, Nowicki M, Augenbraun M, Anastos K, Seaberg E, Rosenberg W, Peters MG| | PubMed
  67. Liver Fibrosis Linked to Cognitive Performance in HIV and Hepatitis C.
    Valcour VG, Rubin LH, Obasi MU, Maki PM, Peters MG, Levin S, Crystal HA, Young MA, Mack WJ, Cohen MH, Pierce CB, Adimora AA, Tien PC, Women's Interagency HIV Study Protocol Team| | PubMed
  68. Marijuana Use Is Not Associated With Progression to Advanced Liver Fibrosis in HIV/Hepatitis C Virus-coinfected Women.
    Kelly EM, Dodge JL, Sarkar M, French AL, Tien PC, Glesby MJ, Golub ET, Augenbraun M, Plankey M, Peters MG| | PubMed
  69. Use of Palliative Care Consultation for Patients with End-Stage Liver Disease: Survey of Liver Transplant Service Providers.
    Beck KR, Pantilat SZ, O'Riordan DL, Peters MG| | PubMed
  70. Interferon Stimulated Gene Expression in HIV/HCV Coinfected Patients Treated with Nitazoxanide/Peginterferon-Alfa-2a and Ribavirin.
    Petersen T, Lee YJ, Osinusi A, Amorosa VK, Wang C, Kang M, Matining R, Zhang X, Dou D, Umbleja T, Kottilil S, Peters MG| | PubMed
  71. Enhanced liver fibrosis marker as a noninvasive predictor of mortality in HIV/hepatitis C virus-coinfected women from a multicenter study of women with or at risk for HIV.
    Peters MG, Bacchetti P, Boylan R, French AL, Tien PC, Plankey MW, Glesby MJ, Augenbraun M, Golub ET, Karim R, Parkes J, Rosenberg W| | PubMed
  72. Acute and Chronic Hepatitis E Virus Infection in Human Immunodeficiency Virus-Infected U.S. Women.
    Kuniholm MH, Ong E, Hogema BM, Koppelman M, Anastos K, Peters MG, Seaberg EC, Chen Y, Nelson KE, Linnen JM| | PubMed
  73. Association of HIV, Hepatitis C Virus, and Liver Fibrosis Severity With the Enhanced Liver Fibrosis Score.
    Swanson S, Ma Y, Scherzer R, Huhn G, French AL, Plankey MW, Grunfeld C, Rosenberg WM, Peters MG, Tien PC| | PubMed
  74. Interferon Lambda 4 Genotype Is Not Associated with Recurrence of Oral or Genital Herpes.
    Lang Kuhs KA, Kuniholm MH, Pfeiffer RM, Chen S, Desai S, Edlin BR, Peters MG, Plankey M, Sharp GB, Strickler HD, Villacres MC, Quinn TC, Gange SJ, Prokunina-Olsson L, Greenblatt RM, O'Brien TR| | PubMed
  75. Association of HIV, hepatitis C virus and liver fibrosis severity with interleukin-6 and C-reactive protein levels.
    Shah S, Ma Y, Scherzer R, Huhn G, French AL, Plankey M, Peters MG, Grunfeld C, Tien PC| | PubMed
  76. A Treatment Algorithm for the Management of Chronic Hepatitis B Virus Infection in the United States: 2015 Update.
    Martin P, Lau DT, Nguyen MH, Janssen HL, Dieterich DT, Peters MG, Jacobson IM| | PubMed
  77. Mother-to-child transmission of hepatitis B virus in sub-Saharan Africa: time to act.
    Andersson MI, Rajbhandari R, Kew MC, Vento S, Preiser W, Hoepelman AI, Theron G, Cotton M, Cohn J, Glebe D, Lesi O, Thursz M, Peters M, Chung R, Wiysonge C| | PubMed
  78. Turnover rates of hepatic collagen and circulating collagen-associated proteins in humans with chronic liver disease.
    Decaris ML, Emson CL, Li K, Gatmaitan M, Luo F, Cattin J, Nakamura C, Holmes WE, Angel TE, Peters MG, Turner SM, Hellerstein MK| | PubMed
  79. Direct and Indirect Serum Markers of Liver Fibrosis Compared with Transient Elastography among Women in the Women's Interagency HIV Study.
    Kassaye S, Li Y, Huhn G, Peters MG, French AL, Tien PC, Luxon B, Plankey MW| | PubMed
  80. Survey of Asian patients with hepatitis B infection: limited knowledge of transmission and screening of family members.
    Vijayan T, Zheng P, Nguyen C, Brown AM, Chen YW, Peters MG| | PubMed
  81. Association of chronic hepatitis C infection with T-cell phenotypes in HIV-negative and HIV-positive women.
    Kuniholm MH, Xie X, Anastos K, Kaplan RC, Xue X, Kovacs A, Peters MG, Seaberg EC, French AL, Young MA, Augenbraun M, Martinson JA, Bush KA, Landay AL, Strickler HD| | PubMed
  82. Advances in therapy for HIV/hepatitis C virus-coinfected patients in the liver transplant setting.
    Campos-Varela I, Peters MG, Terrault NA| | PubMed
  83. Characteristics and management of patients with chronic hepatitis B in an integrated care setting.
    Sarkar M, Shvachko VA, Ready JB, Pauly MP, Terrault NA, Peters MG, Manos MM| | PubMed
  84. Addition of nitazoxanide to PEG-IFN and ribavirin to improve HCV treatment response in HIV-1 and HCV genotype 1 coinfected persons naïve to HCV therapy: results of the ACTG A5269 trial.
    Amorosa VK, Luetkemeyer A, Kang M, Johnson VA, Umbleja T, Haas DW, Yesmin S, Bardin MC, Chung RT, Alston-Smith B, Tebas P, Peters MG| | PubMed
  85. Liver disease in women: the influence of gender on epidemiology, natural history, and patient outcomes.
    Guy J, Peters MG| | PubMed
  86. Association of the IFNL4-ΔG Allele With Impaired Spontaneous Clearance of Hepatitis C Virus.
    Aka PV, Kuniholm MH, Pfeiffer RM, Wang AS, Tang W, Chen S, Astemborski J, Plankey M, Villacres MC, Peters MG, Desai S, Seaberg EC, Edlin BR, Strickler HD, Thomas DL, Prokunina-Olsson L, Sharp GB, O'Brien TR| | PubMed
  87. Age-dependent hepatic lymphoid organization directs successful immunity to hepatitis B.
    Publicover J, Gaggar A, Nishimura S, Van Horn CM, Goodsell A, Muench MO, Reinhardt RL, van Rooijen N, Wakil AE, Peters M, Cyster JG, Erle DJ, Rosenthal P, Cooper S, Baron JL| | PubMed
  88. Association of HIV infection, hepatitis C virus infection, and metabolic factors with liver stiffness measured by transient elastography.
    Bailony MR, Scherzer R, Huhn G, Plankey MW, Peters MG, Tien PC| | PubMed
  89. Suppression of HBV by tenofovir in HBV/HIV coinfected patients: a systematic review and meta-analysis.
    Price H, Dunn D, Pillay D, Bani-Sadr F, de Vries-Sluijs T, Jain MK, Kuzushita N, Mauss S, Núñez M, Nüesch R, Peters M, Reiberger T, Stephan C, Tan L, Gilson R| | PubMed
  90. Microbial translocation and liver disease progression in women coinfected with HIV and hepatitis C virus.
    French AL, Evans CT, Agniel DM, Cohen MH, Peters M, Landay AL, Desai SN| | PubMed
  91. Hepatitis C viremia is associated with cytomegalovirus IgG antibody levels in HIV-infected women.
    Kuniholm MH, Parrinello CM, Anastos K, Augenbraun M, Plankey M, Nowicki M, Peters M, Golub ET, Lurain N, Landay AL, Strickler HD, Kaplan RC| | PubMed
  92. Genome-wide association study of spontaneous resolution of hepatitis C virus infection: data from multiple cohorts.
    Duggal P, Thio CL, Wojcik GL, Goedert JJ, Mangia A, Latanich R, Kim AY, Lauer GM, Chung RT, Peters MG, Kirk GD, Mehta SH, Cox AL, Khakoo SI, Alric L, Cramp ME, Donfield SM, Edlin BR, Tobler LH, Busch MP, Alexander G, Rosen HR, Gao X, Abdel-Hamid M, Apps R, Carrington M, Thomas DL| | PubMed
  93. Racial/ethnic differences in spontaneous HCV clearance in HIV infected and uninfected women.
    Sarkar M, Bacchetti P, Tien P, Mileti E, French AL, Edlin BR, Keller M, Seaberg E, Nowicki MJ, Young M, Peters MG| | PubMed
  94. Lower liver-related death in African-American women with human immunodeficiency virus/hepatitis C virus coinfection, compared to Caucasian and Hispanic women.
    Sarkar M, Bacchetti P, French AL, Tien P, Glesby MJ, Nowicki M, Plankey M, Gange S, Sharp G, Minkoff H, Peters MG, Women's Interagency HIV Study (WIHS)| | PubMed
  95. Untreated HIV infection is associated with higher blood alcohol levels.
    McCance-Katz EF, Lum PJ, Beatty G, Gruber VA, Peters M, Rainey PM| | PubMed
  96. Assessing mortality in women with hepatitis C virus and HIV using indirect markers of fibrosis.
    Bambha K, Pierce C, Cox C, French AL, Tien PC, Sharp GB, Augenbraun M, Glesby MJ, Villacres MC, Plankey M, Strickler HD, Gange SJ, Peters MG| | PubMed
  97. Provisional guidance on the use of hepatitis C virus protease inhibitors for treatment of hepatitis C in HIV-infected persons.
    Thomas DL, Bartlett JG, Peters MG, Sherman KE, Sulkowski MS, Pham PA| | PubMed
  98. Effects of hepatitis C and HIV on cognition in women: data from the Women's Interagency HIV Study.
    Crystal H, Kleyman I, Anastos K, Lazar J, Cohen M, Liu C, Pearce L, Golub E, Valcour V, Ho A, Strickler H, Peters M, Kovacs A, Holman S, Kreek MJ, Manly J| | PubMed
  99. Validation and modification of simplified diagnostic criteria for autoimmune hepatitis in children.
    Mileti E, Rosenthal P, Peters MG| | PubMed
  100. Challenges and opportunities for hepatitis C drug development in HIV-hepatitis C virus-co-infected patients.
    Soriano V, Sherman KE, Rockstroh J, Dieterich D, Back D, Sulkowski M, Peters M| | PubMed
  101. Resistance patterns and response to entecavir intensification among HIV-HBV-coinfected adults with persistent HBV viremia.
    Luetkemeyer AF, Charlebois ED, Hare CB, Black D, Smith A, Havlir DV, Peters MG| | PubMed
  102. The relation of HLA genotype to hepatitis C viral load and markers of liver fibrosis in HIV-infected and HIV-uninfected women.
    Kuniholm MH, Gao X, Xue X, Kovacs A, Marti D, Thio CL, Peters MG, Greenblatt RM, Goedert JJ, Cohen MH, Minkoff H, Gange SJ, Anastos K, Fazzari M, Young MA, Strickler HD, Carrington M| | PubMed
  103. Hepatic stellate cells regulate immune response by way of induction of myeloid suppressor cells in mice.
    Chou HS, Hsieh CC, Yang HR, Wang L, Arakawa Y, Brown K, Wu Q, Lin F, Peters M, Fung JJ, Lu L, Qian S| | PubMed
  104. Sustained long-term antiviral maintenance therapy in HCV/HIV-coinfected patients (SLAM-C).
    Sherman KE, Andersen JW, Butt AA, Umbleja T, Alston B, Koziel MJ, Peters MG, Sulkowski M, Goodman ZD, Chung RT, AIDS Clinical Trials Group A5178 Study Team| | PubMed
  105. Adipose tissue and metabolic factors associated with steatosis in HIV/HCV coinfection: histology versus magnetic resonance spectroscopy.
    Ghotb A, Noworolski SM, Madden E, Scherzer R, Qayyum A, Pannell J, Ferrell L, Peters M, Tien PC| | PubMed
  106. Complement mediated hepatocytes injury in a model of autoantibody induced hepatitis.
    Tu Z, Li Q, Chou HS, Hsieh CC, Meyerson H, Peters MG, Bu H, Fung JJ, Qian S, Lu L, Lin F| | PubMed
  107. Large-scale candidate gene analysis of spontaneous clearance of hepatitis C virus.
    Mosbruger TL, Duggal P, Goedert JJ, Kirk GD, Hoots WK, Tobler LH, Busch M, Peters MG, Rosen HR, Thomas DL, Thio CL| | PubMed
  108. Specific human leukocyte antigen class I and II alleles associated with hepatitis C virus viremia.
    Kuniholm MH, Kovacs A, Gao X, Xue X, Marti D, Thio CL, Peters MG, Terrault NA, Greenblatt RM, Goedert JJ, Cohen MH, Minkoff H, Gange SJ, Anastos K, Fazzari M, Harris TG, Young MA, Strickler HD, Carrington M| | PubMed
  109. Entering the new era of therapy for HBV and HCV infections.
    Peters MG, Perrillo RP, Jacobson IM, Ross DB, Doo EC, Murray JS, Wong JB| | PubMed
  110. Recommendations for prevention, screening, and diagnosis of HBV and HCV infections.
    Peters MG, Weinbaum C, Tan L, Baine WB, Dienstag JL, Liang TJ, So S| | PubMed
  111. Hepatitis C virus (HCV) quasispecies complexity and selection in HCV/HIV-coinfected subjects treated with interferon-based regimens.
    Sherman KE, Rouster SD, Stanford S, Blackard JT, Shire N, Koziel M, Peters M, Chung RT, AIDS Clinical Trials Group 5071 Study Team| | PubMed
  112. End-stage liver disease in HIV disease.
    Peters MG| | PubMed
  113. Long-term serologic follow-up of isolated hepatitis B core antibody in HIV-infected and HIV-uninfected women.
    French AL, Lin MY, Evans CT, Benning L, Glesby MJ, Young MA, Operskalski EA, Augenbraun M, Peters M| | PubMed
  114. Special populations with hepatitis B virus infection.
    Peters MG| | PubMed
  115. Hepatitis C seropositivity and kidney function decline among women with HIV: data from the Women's Interagency HIV Study.
    Tsui J, Vittinghoff E, Anastos K, Augenbraun M, Young M, Nowicki M, Cohen MH, Peters MG, Golub ET, Szczech L| | PubMed
  116. New therapies for hepatitis C virus infection.
    Soriano V, Peters MG, Zeuzem S| | PubMed
  117. Fourth HIV & Hepatitis Coinfection Workshop; June 19-21, 2008; Madrid, Spain.
    Soriano V, Peters M, Rockstroh J| | PubMed
  118. Risk factors for hepatitis B infection in rural Vietnam.
    Duong TH, Nguyen PH, Henley K, Peters M| | PubMed
  119. Prediction of clinical outcomes in primary biliary cirrhosis by serum enhanced liver fibrosis assay.
    Mayo MJ, Parkes J, Adams-Huet B, Combes B, Mills AS, Markin RS, Rubin R, Wheeler D, Contos M, West AB, Saldana S, Getachew Y, Butsch R, Luketic V, Peters M, Di Bisceglie A, Bass N, Lake J, Boyer T, Martinez E, Boyer J, Garcia-Tsao G, Barnes D, Rosenberg WM| | PubMed
  120. Excellent outcome following down-staging of hepatocellular carcinoma prior to liver transplantation: an intention-to-treat analysis.
    Yao FY, Kerlan RK, Hirose R, Davern TJ, Bass NM, Feng S, Peters M, Terrault N, Freise CE, Ascher NL, Roberts JP| | PubMed
  121. Care of HIV patients with chronic hepatitis B: updated recommendations from the HIV-Hepatitis B Virus International Panel.
    Soriano V, Puoti M, Peters M, Benhamou Y, Sulkowski M, Zoulim F, Mauss S, Rockstroh J| | PubMed
  122. The challenge of diagnosing autoimmune hepatitis: less is more.
    Choi G, Peters MG| | PubMed
  123. Hepatitis resulting from liver-specific expression and recognition of self-antigen.
    Buxbaum J, Qian P, Allen PM, Peters MG| | PubMed
  124. The insulin-like growth factor axis and risk of liver disease in hepatitis C virus/HIV-co-infected women.
    Strickler HD, Howard AA, Peters M, Fazzari M, Yu H, Augenbraun M, French AL, Young M, Gange S, Anastos K, Kovacs A| | PubMed
  125. Influence of cannabis use on severity of hepatitis C disease.
    Ishida JH, Peters MG, Jin C, Louie K, Tan V, Bacchetti P, Terrault NA| | PubMed
  126. Diagnosis and management of hepatitis B virus and HIV coinfection.
    Peters MG| | PubMed
  127. Role of alphavbeta6 integrin in acute biliary fibrosis.
    Wang B, Dolinski BM, Kikuchi N, Leone DR, Peters MG, Weinreb PH, Violette SM, Bissell DM| | PubMed
  128. Awareness of hepatitis C infection among women with and at risk for HIV.
    Cohen MH, Grey D, Cook JA, Anastos K, Seaberg E, Augenbraun M, Burian P, Peters M, Young M, French A| | PubMed
  129. Differences between Caucasian, African American, and Hispanic patients with primary biliary cirrhosis in the United States.
    Peters MG, Di Bisceglie AM, Kowdley KV, Flye NL, Luketic VA, Munoz SJ, Garcia-Tsao G, Boyer TD, Lake JR, Bonacini M, Combes B, PUMPS Group| | PubMed
  130. Prevalence and long-term effects of occult hepatitis B virus infection in HIV-infected women.
    Tsui JI, French AL, Seaberg EC, Augenbraun M, Nowicki M, Peters M, Tien PC| | PubMed
  131. Chronic hepatitis B: a global health problem requiring coherent worldwide treatment strategies.
    Lau G, Marcellin P, Peters M| | PubMed
  132. HIV and liver disease forum: conference proceedings.
    Sherman KE, Peters M, Koziel MJ| | PubMed
  133. Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel.
    Soriano V, Puoti M, Sulkowski M, Cargnel A, Benhamou Y, Peters M, Mauss S, Bräu N, Hatzakis A, Pol S, Rockstroh J| | PubMed
  134. Hematologic toxicity associated with interferon-based hepatitis C therapy in HIV type 1-coinfected subjects.
    Behler CM, Vittinghoff E, Lin F, Chung RT, Peters MG, Robbins GK, Volberding PA| | PubMed
  135. Isolated hepatitis B core antibody is associated with HIV and ongoing but not resolved hepatitis C virus infection in a cohort of US women.
    French AL, Operskalski E, Peters M, Strickler HD, Tien PC, Sharp GB, Glesby MJ, Young M, Augenbraun M, Seaberg E, Kovacs A| | PubMed
  136. Viral hepatitis in HIV infection.
    Koziel MJ, Peters MG| | PubMed
  137. Viral factors associated with cytokine expression during HCV/HIV co-infection.
    Blackard JT, Kang M, St Clair JB, Lin W, Kamegaya Y, Sherman KE, Koziel MJ, Peters MG, Andersen J, Chung RT, Aids Clinical Trials Group A5071 Study Team| | PubMed
  138. Effects of HCV treatment on cytokine expression during HCV/HIV coinfection.
    Blackard JT, Kang M, Sherman KE, Koziel MJ, Peters MG, Chung RT| | PubMed
  139. Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127.
    Peters MG, Andersen J, Lynch P, Liu T, Alston-Smith B, Brosgart CL, Jacobson JM, Johnson VA, Pollard RB, Rooney JF, Sherman KE, Swindells S, Polsky B, ACTG Protocol A5127 Team| | PubMed
  140. Novel model of antigen-specific induction of bile duct injury.
    Buxbaum J, Qian P, Khuu C, Shneider BL, Daikh DI, Gershwin ME, Allen PM, Peters MG| | PubMed
  141. De novo malignancies following liver transplantation: a case-control study with long-term follow-up.
    Yao FY, Gautam M, Palese C, Rebres R, Terrault N, Roberts JP, Peters MG| | PubMed
  142. Eosinophilic hepatitis caused by lamotrigine.
    Fix OK, Peters MG, Davern TJ| | PubMed
  143. Relationships between cellular immune responses and treatment outcomes with interferon and ribavirin in HIV/hepatitis C virus co-infection.
    Graham CS, Wells A, Liu T, Sherman KE, Peters M, Chung RT, Bhan AK, Andersen J, Koziel MJ, ACTG 5071 Study Team| | PubMed
  144. Chronic hepatitis B: a critical appraisal of current approaches to therapy.
    Perrillo RP, Gish RG, Peters M, Keeffe EB, Alberti A, Buti M, Cooksley WG, Fried MW, Hadziyannis SJ, Liaw YF, Naoumov NV, Schiff ER, Thio CL, Tsai N, Schalm S| | PubMed
  145. Clinical presentation and course of acute hepatitis C infection in HIV-infected patients.
    Luetkemeyer A, Hare CB, Stansell J, Tien PC, Charlesbois E, Lum P, Havlir D, Peters M| | PubMed
  146. Methotrexate (MTX) plus ursodeoxycholic acid (UDCA) in the treatment of primary biliary cirrhosis.
    Combes B, Emerson SS, Flye NL, Munoz SJ, Luketic VA, Mayo MJ, McCashland TM, Zetterman RK, Peters MG, Di Bisceglie AM, Benner KG, Kowdley KV, Carithers RL, Rosoff L, Garcia-Tsao G, Boyer JL, Boyer TD, Martinez EJ, Bass NM, Lake JR, Barnes DS, Bonacini M, Lindsay KL, Mills AS, Markin RS, Rubin R, West AB, Wheeler DE, Contos MJ, Hofmann AF| | PubMed
  147. Recurrent primary biliary cirrhosis: peritransplant factors and ursodeoxycholic acid treatment post-liver transplant.
    Guy JE, Qian P, Lowell JA, Peters MG| | PubMed
  148. Managing hepatitis B coinfection in HIV-infected patients.
    Peters MG| | PubMed
  149. Antigen-specific immune responses and liver histology in HIV and hepatitis C coinfection.
    Graham CS, Wells A, Liu T, Sherman KE, Peters M, Chung RT, Bhan AK, Andersen J, Koziel MJ, ACTG 5071 Study Team| | PubMed
  150. Viral kinetics in hepatitis C or hepatitis C/human immunodeficiency virus-infected patients.
    Sherman KE, Shire NJ, Rouster SD, Peters MG, James Koziel M, Chung RT, Horn PS| | PubMed
  151. Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons.
    Chung RT, Andersen J, Volberding P, Robbins GK, Liu T, Sherman KE, Peters MG, Koziel MJ, Bhan AK, Alston B, Colquhoun D, Nevin T, Harb G, van der Horst C, AIDS Clinical Trials Group A5071 Study Team| | PubMed
  152. Antiviral therapy: nucleotide and nucleoside analogs.
    Quan DJ, Peters MG| | PubMed
  153. Prolonged follow-up of patients in the U.S. multicenter trial of ursodeoxycholic acid for primary biliary cirrhosis.
    Combes B, Luketic VA, Peters MG, Zetterman RK, Garcia-Tsao G, Munoz SJ, Lin D, Flye N, Carithers RL| | PubMed
  154. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B.
    Peters MG, Hann Hw Hw, Martin P, Heathcote EJ, Buggisch P, Rubin R, Bourliere M, Kowdley K, Trepo C, Gray Df Df, Sullivan M, Kleber K, Ebrahimi R, Xiong S, Brosgart CL| | PubMed
  155. Hepatitis C and alcohol: fundamental and translational research directions.
    Morgan TR, Brenner D, Everhart J, French SW, Fried MW, Gretch DR, Koziel MJ, McClain CJ, Peters MG, Weinman SA, Lucas DL| | PubMed
  156. Detection of primary hepatic malignancy in liver transplant candidates: prospective comparison of CT, MR imaging, US, and PET.
    Teefey SA, Hildeboldt CC, Dehdashti F, Siegel BA, Peters MG, Heiken JP, Brown JJ, McFarland EG, Middleton WD, Balfe DM, Ritter JH| | PubMed
  157. Alcohol use and hepatitis C.
    Peters MG, Terrault NA| | PubMed
  158. Animal models of autoimmune liver disease.
    Peters MG| | PubMed